News

The FDA gave volixibat a special approval as a potential treatment for itching in patients with primary biliary cholangitis.

A new study suggests which method is superior for detecting genetic variables associated with primary biliary cholangitis (PCB).

A recently published case report described a pregnant patient diagnosed with PBC, hypertension and preeclampsia.

Results were positive from a 120-day phase 2a study of CNP-104, a proposed treatment for primary biliary cholangitis.

In a recent study, patients with PBC experienced more muscle loss, itching and malnutrition than patients with other liver disorders.

The U.S. Food and Drug Administration gave accelerated approval for seladelpar to treat primary biliary cholangitis (PBC).

Changes in the gut microbiome configuration could negatively affect the response to ursodeoxycholic acid (UDCA) treatment in patients with primary biliary cholangitis (PBC), according to a recently published study in Med. “These findings suggest that baseline microbial composition may predict treatment response and offer novel insights into PBC pathogenesis,” the study concluded. UDCA represents first-line […]

Results from the first epigenome-wide association study of patients with PBC and PSC have been recently published.

A recent study showed improvement of the gut microbiota may be a critical aspect of PBC prevention and treatment.

Treatment with obeticholic acid (OCA) improved outcomes for primary biliary cholangitis (PBC) patients in a recent clinical trial.